JP2024522990A - 抗ウイルス薬としてのプロテアーゼ阻害剤 - Google Patents

抗ウイルス薬としてのプロテアーゼ阻害剤 Download PDF

Info

Publication number
JP2024522990A
JP2024522990A JP2023574150A JP2023574150A JP2024522990A JP 2024522990 A JP2024522990 A JP 2024522990A JP 2023574150 A JP2023574150 A JP 2023574150A JP 2023574150 A JP2023574150 A JP 2023574150A JP 2024522990 A JP2024522990 A JP 2024522990A
Authority
JP
Japan
Prior art keywords
mixture
compound
alkyl
tautomers
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522990A5 (cg-RX-API-DMAC10.html
Inventor
ロン マオ，
シャオ シュー，
ナミール シャーバニ，
カン ジン，
Original Assignee
エイシア セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシア セラピューティクス， インコーポレイテッド filed Critical エイシア セラピューティクス， インコーポレイテッド
Publication of JP2024522990A publication Critical patent/JP2024522990A/ja
Publication of JP2024522990A5 publication Critical patent/JP2024522990A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
JP2023574150A 2021-06-02 2022-06-01 抗ウイルス薬としてのプロテアーゼ阻害剤 Pending JP2024522990A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195930P 2021-06-02 2021-06-02
US63/195,930 2021-06-02
US202163275113P 2021-11-03 2021-11-03
US63/275,113 2021-11-03
PCT/US2022/031815 WO2022256434A1 (en) 2021-06-02 2022-06-01 Protease inhibitors as antivirals

Publications (2)

Publication Number Publication Date
JP2024522990A true JP2024522990A (ja) 2024-06-25
JP2024522990A5 JP2024522990A5 (cg-RX-API-DMAC10.html) 2025-06-10

Family

ID=82321542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574150A Pending JP2024522990A (ja) 2021-06-02 2022-06-01 抗ウイルス薬としてのプロテアーゼ阻害剤

Country Status (12)

Country Link
US (3) US11753373B2 (cg-RX-API-DMAC10.html)
EP (1) EP4347034A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024522990A (cg-RX-API-DMAC10.html)
KR (1) KR20240057384A (cg-RX-API-DMAC10.html)
CN (1) CN122277534A (cg-RX-API-DMAC10.html)
AU (1) AU2022283816A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025358A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220847A1 (cg-RX-API-DMAC10.html)
IL (1) IL308694A (cg-RX-API-DMAC10.html)
MX (1) MX2023014307A (cg-RX-API-DMAC10.html)
TW (1) TW202313567A (cg-RX-API-DMAC10.html)
WO (1) WO2022256434A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4635972A3 (en) * 2020-07-20 2025-12-24 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2022109360A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US20240043417A1 (en) * 2020-12-01 2024-02-08 Purdue Research Foundation Compounds for the treatment of sars
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
JP2024522990A (ja) 2021-06-02 2024-06-25 エイシア セラピューティクス， インコーポレイテッド 抗ウイルス薬としてのプロテアーゼ阻害剤
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023093834A1 (zh) * 2021-11-26 2023-06-01 先声再明医药有限公司 一种吡咯烷类抗病毒化合物
WO2023107417A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
TW202334123A (zh) * 2021-12-31 2023-09-01 大陸商蘇州愛科百發生物醫藥技術有限公司 用於預防和治療冠狀病毒感染的化合物及其偶聯物和方法
WO2023134730A1 (zh) * 2022-01-13 2023-07-20 先声再明医药有限公司 一种酰胺类抗病毒化合物
US12145942B2 (en) 2022-04-05 2024-11-19 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN116535460A (zh) * 2023-04-28 2023-08-04 中国人民解放军军事科学院军事医学研究院 一类含硫拟肽类化合物及其制备方法和用途
WO2024237816A1 (ru) * 2023-05-12 2024-11-21 Общество С Ограниченной Ответственностью "Промомед Рус" Новые производные азабициклогексана
WO2025011610A1 (zh) * 2023-07-13 2025-01-16 深圳市塔吉瑞生物医药有限公司 酰胺衍生物及其组合物及用途
EP4686470A1 (en) 2024-08-01 2026-02-04 Ospedale San Raffaele S.r.l. Macrocyclic peptidomimetics as antiviral agents

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066123A1 (en) * 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2020030143A1 (zh) * 2018-08-09 2020-02-13 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途
WO2021205296A1 (en) * 2020-04-05 2021-10-14 Pfizer Inc. Method of treating covid-19
WO2021206876A1 (en) * 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
WO2021216195A1 (en) * 2020-04-23 2021-10-28 Purdue Research Foundation Compounds for the treatment of sars
WO2021252644A1 (en) * 2020-06-09 2021-12-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2021250648A1 (en) * 2020-09-03 2021-12-16 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113580A1 (en) * 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2020247565A1 (en) 2019-06-05 2020-12-10 Rhodia Operations Oral care composition
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
US11124497B1 (en) * 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
CN116547294A (zh) * 2020-08-13 2023-08-04 英安塔制药有限公司 作为抗病毒剂的功能化肽
JP2024522990A (ja) 2021-06-02 2024-06-25 エイシア セラピューティクス， インコーポレイテッド 抗ウイルス薬としてのプロテアーゼ阻害剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066123A1 (en) * 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2020030143A1 (zh) * 2018-08-09 2020-02-13 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途
WO2021205296A1 (en) * 2020-04-05 2021-10-14 Pfizer Inc. Method of treating covid-19
WO2021206876A1 (en) * 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
WO2021216195A1 (en) * 2020-04-23 2021-10-28 Purdue Research Foundation Compounds for the treatment of sars
WO2021252644A1 (en) * 2020-06-09 2021-12-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2021250648A1 (en) * 2020-09-03 2021-12-16 Pfizer Inc. Nitrile-containing antiviral compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CITARELLA ANDREA; ET AL: "SARS-COV-2 M<PRO>: A POTENTIAL TARGET FOR PEPTIDOMIMETICS AND SMALL-MOLECULE INHIBITORS", BIOMOLECULES, vol. VOL.11, NR.4, JPN5025002972, 19 April 2021 (2021-04-19), CH, pages 607 - 1, ISSN: 0005819994 *
DAI, WENHAO ET AL.: "Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel S", BIORXIV, JPN7026001119, 2020, pages 1 - 17, ISSN: 0005819993 *
HOFFMAN, ROBERT L. ET AL.: "Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therape", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63(21), JPN7026001122, 2020, pages 12725 - 12747, ISSN: 0005819999 *
REGISTRY（STN）[ONLINE], JPN7026001121, ISSN: 0005819996 *
THANIGAIMALAI PILLAIYAR; ET AL: "DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL DIPEPTIDE-TYPE SARS-COV 3CL PROTEASE INHIBITOR", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 65, JPN5025002974, 20 May 2013 (2013-05-20), NL, pages 436 - 447, ISSN: 0005819998 *
TIEW KOK-CHUAN; ET AL: "DESIGN, SYNTHESIS, AND EVALUATION OF INHIBITORS OF NORWALK VIRUS 3C PROTEASE", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. VOL.21, NR.18, JPN5025002973, 14 July 2011 (2011-07-14), NL, pages 5315 - 5319, ISSN: 0005819997 *
VUONG, WAYNE ET AL.: "Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, i", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 222, JPN7026001120, 30 May 2021 (2021-05-30), pages 1 - 11, ISSN: 0005819995 *

Also Published As

Publication number Publication date
US20230322668A1 (en) 2023-10-12
KR20240057384A (ko) 2024-05-02
US11753373B2 (en) 2023-09-12
MX2023014307A (es) 2024-04-05
US20250122153A1 (en) 2025-04-17
US11987554B2 (en) 2024-05-21
WO2022256434A1 (en) 2022-12-08
TW202313567A (zh) 2023-04-01
AU2022283816A1 (en) 2024-01-04
US20230026438A1 (en) 2023-01-26
IL308694A (en) 2024-01-01
BR112023025358A2 (pt) 2024-02-27
EP4347034A1 (en) 2024-04-10
CN122277534A (zh) 2026-06-26
CA3220847A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
US11987554B2 (en) Protease inhibitors as antivirals
TWI846527B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
ES3000422T3 (en) Nitrile-containing compounds for use as medicaments
JP7163379B2 (ja) Ｉｌ－１７調節剤としてのスピロ環インドリン
AU2019351494B2 (en) Nitroxoline prodrug and use thereof
CN115785124A (zh) Kras g12d抑制剂及其用途
CN109563133B (zh) 多酰胺化合物及其用途
GB2510407A (en) Aqueous suspensions of kallikrein inhibitors for parenteral administration
WO2024149360A1 (zh) 一种双季铵盐化合物及其在医药上的应用
WO2024193464A1 (zh) 一种含氮三并环衍生物及其在医药上的应用
ES2653931T3 (es) Tiazolo y oxazolo-pirimidinonas condensadas
JP2025518741A (ja) ミトコンドリア機能関連疾患治療用の３－アザステロイド化合物
CN117769541A (zh) 作为抗病毒剂的蛋白酶抑制剂
KR20190032534A (ko) C5a 수용체 길항제로서의 시클릭 펩티드
BR112021011189A2 (pt) Ácidos biliares 2-fluorados para o tratamento de transtornos neurodegenerativos
TW201416363A (zh) Ｃ型肝炎病毒抑制劑
ES2307410B1 (es) S-nitrosotioles estables, procedimiento de sintesis y uso.
TWI874355B (zh) 硝羥喹啉前藥及其用途
WO2025044860A1 (zh) 神经激肽-1受体拮抗剂化合物
CN121511247A (zh) 河豚毒素衍生物化合物及其作为钠通道阻滞剂的用途
WO2022003557A1 (en) Novel inhibitors of autotaxin
EA052837B1 (ru) Пролекарства ганаксолона
HK40047998A (en) Nitroxoline prodrug and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260318